Jialiang (nmn) Wang
CIK: 0002133226
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
GYRE
GYRE THERAPEUTICS, INC.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Wang Jialiang (NMN)
Wang Jialiang (NMN) (SEC CIK 0002133226) files insider reports with the SEC as EVP, General Manager of GYRE THERAPEUTICS, INC. (GYRE).
Signal8 holds 1 ownership filing by Wang Jialiang (NMN), a Form 3, filed on May 7, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Wang Jialiang (NMN)'s filings is in SAN DIEGO, CA.
Other insiders filing for GYRE THERAPEUTICS, INC. (GYRE)
- Weston Claire, Director
- Kirkby Maxwell, Director
- Ye Weiguo, Chief Operating Officer
- Bergmann Joshua Benjamin, GC and Corporate Secretary
- Luo Ying, Chief Executive Officer
- Zhang Ping, Director